Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arian Lasocki

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Neuro-Oncology Practice|April 8, 2020
Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobankingCraig Gedye, Mythily Sachchithananthan, Robyn Leonard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.
BMJ Neurology Open|March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapyDaniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Frontiers in Endocrinology|December 14, 2023
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitisAnna Galligan, Amir Iravani, Arian Lasocki, et al.
Journal of Neuro-Oncology|October 7, 2020
Correction to: Serum microRNA is a biomarker for post-operative monitoring in gliomaAndrew Morokoff, Jordan Jones, Hong Nguyen, et al.
Journal of Neuro-Oncology|September 11, 2020
Serum microRNA is a biomarker for post-operative monitoring in gliomaAndrew Morokoff, Jordan Jones, Hong Nguyen, et al.
Journal for Immunotherapy of Cancer|October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Neuro-Oncology Practice|April 8, 2020
Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobankingCraig Gedye, Mythily Sachchithananthan, Robyn Leonard, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.
BMJ Neurology Open|March 25, 2026
Neurological implications of chimeric antigen receptor-T cell therapyDaniel G Raffoul, Izanne Roos, Matthias Mulazzani, et al.
Frontiers in Endocrinology|December 14, 2023
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitisAnna Galligan, Amir Iravani, Arian Lasocki, et al.
Journal of Neuro-Oncology|October 7, 2020
Correction to: Serum microRNA is a biomarker for post-operative monitoring in gliomaAndrew Morokoff, Jordan Jones, Hong Nguyen, et al.
Journal of Neuro-Oncology|September 11, 2020
Serum microRNA is a biomarker for post-operative monitoring in gliomaAndrew Morokoff, Jordan Jones, Hong Nguyen, et al.
Journal for Immunotherapy of Cancer|October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.
BMJ Open|August 4, 2023
[<sup>18</sup>F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: protocol for a prospective, multicentre PET/CT trialEng-Siew Koh, Hui K Gan, Clare Senko, et al.
Pageof 6